Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Antiviral Res. 2021 May 30;193:105084. doi: 10.1016/j.antiviral.2021.105084

Fig. 3.

Fig. 3.

Luciferase-expressing recombinant CedV as a tool for antiviral testing. rCedV-Luc (MOI: 0.01) was incubated with medium or an equal volume of m14F3 diluted in medium at a final concentration of 20 μg/ml for 1 h at 37 °C. The antibody-virus or virus only mixtures were then added to HEK 293T cells pre-seeded in a white opaque 96-well cell culture plate, such that 16 wells contained rCedV-Luc and 16 wells contained rCedV-Luc with m14F3. Mock infected cells were included as an additional control. The plate was incubated for 1 h at 37 °C, at which time the antibody-virus or virus only mixtures were removed, cells were washed once with medium, and fresh medium only or fresh medium containing 20 μg/ml m14F3 was added to the cells. After a 48 h incubation, all cells were lysed and relative light units (RLU) in the rCedV-Luc infected cells were measured. The data represent mean ± standard error from two independent experiments. * P<0.01.